Pioneering Cancer treatment technology backed by London Seed Capital

Entities Mentioned

• Michelson Diagnostics
• University College Hospital
• Jon Holmes

1. Optical imaging company Michelson Diagnostics has secured £600,000 of early stage funding, enabling it to further enhance its pioneering technology and pursue in-vivo trials in a clinical environment. This innovative, next generation, imaging technology addresses the key need for clinicians to see, during an operation and in real time, the location and extent of a tumour, for a range of cancer types. This enables faster, more accurate cancer surgery, with the associated benefits for the patient and clinician, when compared with the slow, painstaking process of taking multiple samples of tissue for analysis. (Read Full Article)
   
   

   Related Articles

   • Optical Coherence Tomography Market to Top $800 Million by 2012
   • also categorized in Funding
   • Imalux Awarded $2.3 Million Research Grant
   • also categorized in Funding
   • Start-up spotlight: Michelson Diagnostics
   • also mentions Michelson Diagnostics
   • OCT market to top $800 million by 2012
   • also categorized in Funding
   • OCT imaging of oral cancer tissue announced by MDL and UCH
   • also mentions University College Hospital

   • Successful OCT imaging during cancer surgery
   • also mentions Jon Holmes
   • Optical Coherence Tomography Market to Top $800 Million by 2012
   • also categorized in Funding
   • Optovue, an ocular disease treatment co., raises $10.5M
   • also categorized in Funding
   • Imalux Awarded $2.3 Million Research Grant
   • also categorized in Funding
   • Optical Coherence Tomography Market To Top $800 Million By 2012
   • also categorized in Funding

Login to comment.